{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-26-000088","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2026-08-05T11:41:04+00:00","discovered_at":"2026-08-05T11:45:03.277603+00:00","generated_at":"2026-08-05T11:45:18.087267+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immuneering reports 17.3mo OS in pancreatic cancer; Q2 net loss $17.3M","bullets":["Net loss of $17.3M ($0.27/share) in Q2 2026 vs $14.4M ($0.40/share) in Q2 2025; R&D expenses rose to $14.0M from $10.5M.","Cash, equivalents and marketable securities $182.7M as of June 30, 2026, down from $217.0M at Dec 31, 2025; runway into 2029.","Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer is dosing patients; over 30 study locations posted.","Phase 2a data at ASCO showed 17.3-month median overall survival in 55 patients; 84% weight stable or gained weight at 3 months.","Appointed Andrew Gengos as CFO; he previously served as CFO of Terns Pharmaceuticals (acquired by Merck for $6.7B)."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-26-000088","json":"https://secwatch.observer/filing/0001790340-26-000088.json","markdown":"https://secwatch.observer/filing/0001790340-26-000088.md","text":"https://secwatch.observer/filing/0001790340-26-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/0001790340-26-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:45:18.087267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}